DMK Pharmaceuticals (NASDAQ: DMK) is a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders.The commercially approved products include ZIMHI® (naloxone) and SYMJEPI®. ZIMHI® (naloxone) Injection is FDA approved for opioid overdose emergency rescue. SYMJEPI® (epinephrine) Injection is FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis.